Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 51 clinical trials
Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

, carfilzomib has demonstrated robust and durable activity in heavily pre-treated patients with RRMM in phase I and II trials The idea of combining a PI and an immunomodulatory drug (IMiD) such as thalidomide

  • 22 views
  • 21 Jan, 2021
  • 1 location
Elotuzumab in Combination With Carfilzomib Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM

Of the next-generation compounds, the monoclonal antibodies (moAbs) have recently attracted a lot of interest in MM. The anti-SLAMF7 directed moAb elotuzumab has completed phase III trials in MM patients. One phase III trial in MM patients with one to three prior lines of therapy compared elotuzumab-Rd with standard Rd. …

  • 8 views
  • 03 Mar, 2021
  • 58 locations
Thalidomide Maintenance Treatment in DLBCL

This is a randomized, multi-center,phase III study to evaluate the ability of thalidomide maintenance therapy to prolong relapse-free survival in diffuse large B cell lymphoma(DLBCL).

b-cell lymphoma
rituximab
  • 15 views
  • 21 Jan, 2021
  • 1 location
Radiotherapy Plus Thalidomide in Locally Advanced Hepatocellular Carcinoma

This is a pilot study of concomitant radiotherapy and thalidomide for patients with locally advanced HCC.Besides toxicity and efficacy, mechanistic studies including dynamic contrast

hepatoma
systemic therapy
cirrhosis
ct scan
thalidomide
  • 1 views
  • 07 Nov, 2020
  • 1 location
Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular Carcinoma

cirrhosis due to toxicity of chemotherapeutic agent to the parenchyma liver. Thalidomide has been reported to have antiangiogenic and antimetastatic effects. The objectives of adjuvant therapy

antineoplastic
thalidomide
chemoembolization
cirrhosis
TACE
  • 1 views
  • 07 Nov, 2020
  • 1 location
PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma

Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive form of non-Hodgkin's lymphoma and shows extremely poor survival. This prospective pilot study to evaluate the efficacy and safety of long-acting aspargase (pegylated aspargase, PEG-ASP) combined with gemcitabine and oxaliplatin (PASP -Gemox) treatment in this population.

  • 1 views
  • 22 Mar, 2021
  • 1 location
Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)

the efficacy and toxicity of thalidomide in combination with chemotherapy and as maintenance treatment in patients with advanced non-squamous NSCLC.

  • 0 views
  • 23 Jan, 2021
  • 2 locations
Thalidomide Cyclophosphamide Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma

Background: In some studies, thalidomide in combination with chemotherapy has been shown to be effective in patients with relapsed or refractory multiple myeloma (MM). In this study, the

cyclophosphamide
dexamethasone
induction therapy
maintenance therapy
progressive disease
  • 8 views
  • 07 Nov, 2020
  • 1 location
Thalidomide and Tegafur/Uracil(UFUR) in the Treatment of Advanced Colorectal Cancer

. Thalidomide is an agent, which has shown potential in the treatment of hematological and solid tissue malignancies such as multiple myeloma via antiangiogenic mechanism. Tegafur/uracil (UFUR) is one

irinotecan
antineoplastic
neutrophil count
oxaliplatin
metastasis
  • 7 views
  • 07 Nov, 2020
  • 1 location
A Phase II Study of Tegafur/Uracil (UFUR )Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC)

Primary objective: To evaluate the overall response rate of tegafur/uracil (UFUR®) and thalidomide in the treatment of advanced or metastatic hepatocellular carcinoma. Secondary

arterial embolization
hepatitis
ct scan
measurable disease
local therapy
  • 4 views
  • 07 Nov, 2020
  • 1 location